Tivic Health Systems Reports Q2 2025 Earnings, Focuses on Prescription Therapeutics, Secures Exclusive License for TLR5 Agonist Platform, and Strengthens Cash Position.

Tivic Health Systems reported Q2 2025 earnings with revenue of $86,000, a gross margin of 63%, and a net loss of $1.9 million. The company plans to exit the consumer health technology business and focus on prescription-based therapeutics. Tivic obtained an exclusive license for Sotero Biopharma's TLR5 agonist portfolio, including late-stage entolimod and Entelaspa candidates. Entolimod has fast track designation for ARS and orphan drug status for pediatric ARS.